BioInsights - Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?

Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?

Cell & Gene Therapy Insights 2020; 6(9), 1103–1108

10.18609/cgti.2020.118

Published: 22 September 2020
Commentary
David Gilham

Dr David Gilham first joined Celyad Oncology in April 2016 as a member of the Scientific Advisory Board. As of September 1, 2016, David became Vice-President R&D, heading the implementation of our research and development strategy for our programs in immuno-oncology. Dr. Gilham received his Ph.D. in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins. The group moved to Manchester in 1998 where his research activity has focused on engineering T-cells for cancer therapy and developing the necessary pre-clinical studies to support translation of this therapy into Phase 1/2 clinical trials in Manchester. Prior to joining Celyad Oncology, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre.